RecruitingRecruiting
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650 · Hanmi Pharmaceutical Company Limited
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus
About this study
HM-OBCT-202 is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, parallel-group study designed to evaluate the efficacy, safety, and tolerability of HM15275 treatment over 36 weeks in adults with type 2 diabetes mellitus (T2DM).
The study will enroll adult participants with T2DM (aged 18 to 75 years) who have inadequate glycemic control. Eligible participants must have a body mass index (BMI) ≥25 kg/m² and ≤50 kg/m² and HbA1c between 7.0% and 10.0% at screening.
Participants in this study will be randomly assigned in a 1:1:1:1 ratio to 1 of the 4 treatment arms. Randomization will be stratified by screening HbA1c (≤8.0% versus \>8.0%) and use of metformin (yes versus no).
All participants will undergo a 4-week screening period, a 36-week treatment period (including weekly subcutaneous \[SC\] injection of study drug), and a 4-week safety follow-up period.
Eligibility criteria
Key Inclusion Criteria
1. Participant's age at the time of signing the informed consent:
* United States: 18 to 75 years (inclusive)
2. Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening
3. Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for at least 3 months prior to screening
4. BMI ≥25 kg/m² and ≤50 kg/m²
5. Body weight change \<5% over the past 3 months prior to screening
6. Capable of giving signed informed consent and willing to comply with all protocol procedures
Key Exclusion Criteria
1. Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening
2. Poor glycemic control (fasting plasma glucose \>270 mg/dL)
3. History of diabetic ketoacidosis or severe hypoglycemia within 6 months
4. Clinically significant cardiovascular disease (e.g., NYHA class III/IV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months)
5. History of pancreatitis or factors increasing the risk of pancreatitis
6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2
7. Clinically significant liver disease, renal impairment (eGFR \<60 mL/min/1.73 m²), or abnormal laboratory findings at screening
8. Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening
Study design
Enrollment target: 180 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-05-18
Estimated completion: 2027-10
Last updated: 2026-10-19
Interventions
Drug: HM15275Drug: Placebo of HM15275
Primary outcomes
- • Change in Glycated Hemoglobin (HbA1c) (Up to 41 weeks)
Sponsor
Hanmi Pharmaceutical Company Limited · industry
Contacts & investigators
ContactPureun Nam · contact · pureun.nam@hanmi.co.kr · +82-2-410-9147
ContactHyeonho Choi · contact · hyeonho.choi@hanmi.co.kr · +82-2-410-9834
All locations (20)
Desert Clinical ResearchRecruiting
Mesa, Arizona, United States
Care Access Research - Santa ClaritaRecruiting
Santa Clarita, California, United States
Accel Research Sites - DeLandRecruiting
DeLand, Florida, United States
Charter ResearchRecruiting
Orlando, Florida, United States
AdventHealth Translational Research InstituteRecruiting
Orlando, Florida, United States
K2 Medical Research The Villages LLCRecruiting
The Villages, Florida, United States
Charter Research - The VillagesRecruiting
The Villages, Florida, United States
Centricity Research IRT - DBA IACT Health Columbus PiedmontRecruiting
Columbus, Georgia, United States
Charter Research - ChicagoRecruiting
Chicago, Illinois, United States
The South Bend ClinicRecruiting
South Bend, Indiana, United States
Jefferson City Medical CenterRecruiting
Jefferson City, Missouri, United States
Clay Platte Family MedicineRecruiting
Kansas City, Missouri, United States
Methodist Physicians ClinicRecruiting
Fremont, Nebraska, United States
Santa Rosa Medical Centers of NevadaRecruiting
Las Vegas, Nevada, United States
Lucas Research, Inc.Recruiting
Morehead City, North Carolina, United States
Centricity Research ColumbusRecruiting
Columbus, Ohio, United States
DM Clinical ResearchRecruiting
Tomball, Texas, United States
Olympus Family MedicineRecruiting
Salt Lake City, Utah, United States
Highland Clinical ResearchRecruiting
Salt Lake City, Utah, United States
Manassas Clinical Research CenterRecruiting
Manassas, Virginia, United States